Curocell Inc. (KOSDAQ:372320)

South Korea flag South Korea · Delayed Price · Currency is KRW
43,650
+100 (0.23%)
At close: Dec 29, 2025
45.26%
Market Cap629.98B
Revenue (ttm)n/a
Net Income (ttm)-39.26B
Shares Out14.43M
EPS (ttm)-2,755.02
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume125,429
Average Volume150,528
Open44,100
Previous Close43,550
Day's Range43,000 - 45,500
52-Week Range23,750 - 49,000
Beta1.49
RSI55.64
Earnings DateMar 13, 2026

About Curocell

Curocell Inc. develops CAR-T cell therapy for the treatment of cancer. It focuses on the development of CD19 CAR-T for the treatment of lymphoma; and BCMA CAR-T for the treatment of multiple myeloma. The company was incorporated in 2016 and is based in Daejeon, South Korea. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2016
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 372320
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.